Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer

Prostate cancer patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer. Resistance can occur when mutations in the androgen receptor (AR) render anti-androgen drugs ineffective or through the expression of constitutively active splice variants...

Full description

Bibliographic Details
Main Authors: Fuqiang Ban, Eric Leblanc, Ayse Derya Cavga, Chia-Chi Flora Huang, Mark R. Flory, Fan Zhang, Matthew E. K. Chang, Hélène Morin, Nada Lallous, Kriti Singh, Martin E. Gleave, Hisham Mohammed, Paul S. Rennie, Nathan A. Lack, Artem Cherkasov
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
castration resistant prostate cancer
androgen receptor inhibitor
N-terminal domain
small molecule inhibitor
computer-aided drug design
AR splice variants
Online Access:https://www.mdpi.com/2072-6694/13/14/3488

Internet

https://www.mdpi.com/2072-6694/13/14/3488

Similar Items